This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of lung cancer and melanoma.

This report provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence.

This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the breast- and prostate cancer field.

The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of breast cancer drugs by company and by stage as well as a summary of the latest news and developments in this area.

Overview and analysis of the 20 leading cancer therapy brands in each of the seven major markets based on 2007 sales. Includes forecasts to 2017 in light of key events set to influence product sales and an in-depth review of market dynamics.

In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of non-hodgkin lymphoma drugs by company and by stage as well as a summary of the latest news and developments in this area.

This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landsca

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of non-small-cell lung cancer or lung cancer or small cell lung cancer drugs by company and by stage as well as a summary of the latest news and de

There are today no less than 190 therapeutics targeting melanoma, from early preclinical to marketed drugs. Melanoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to more than 13

First of its kind, "Antibody Drug Target Atlas in Oncology" provides a comprehensive analysis of the commercialization of antibody drug targets in oncology

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major market

With this report you will be able to track down and foresee activities associated with the development of new treatments for NSCLC.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of liver cancer drugs by company and by stage as well as a summary of the latest news and developments in this area.

This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of acute lymphoblastic leukemia or leukemia or chronic lymphocytic leukemia or chronic myelogenous leukemia or acute myelogenous leukemia or hairy

This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis.

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates.

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Breast- and Prostate Cancer, which are all subjects to an extensive number of innovative drug candidates.

Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal th

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of prostate cancer drugs by company and by stage as well as a summary of the latest news and developments in this area.

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs.

This report provides a detailed insight into both cancer therapeutics and diagnostics, to provide a clear vision of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities, highlighting

This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own

This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field.

The purpose of this report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer.

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only

There are today more than 90 therapeutics targeting liver cancer, from early preclinical to marketed drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 67 diffe